# Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Source: https://onco.cc/trials/nct06126510/  
OnCo record `nct06126510` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) in sarcomas, run by CNBG-Virogin Biotech (Shanghai) Ltd., now recruiting.

## Summary

Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06126510 by CNBG-Virogin Biotech (Shanghai) Ltd., with 40 participants planned, started 2023-07-18 and due to reach its primary completion in 2025-07-17. Interventions recorded: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06126510
- Phase: 2
- Setting: A Single-arm, Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
- Sponsor: CNBG-Virogin Biotech (Shanghai) Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06126510: https://clinicaltrials.gov/study/NCT06126510

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06126510.json